Depot Medroxyprogesterone & Meningioma Risk in Women
- A population-based study published in JAMA Neurology reveals that women using depot medroxyprogesterone acetate (DMPA, depo-Provera; Pfizer)-a long-acting injectable contraceptive-face a notably higher risk of being diagnosed with...
- meningiomas represent the most common form of primary brain tumor, and although most are noncancerous, they remain clinically significant.
- "Meningioma is the only intracranial tumor with a clear predominance in women,with increasing incidence after puberty (from 2 to 3.5:1)," wrote Gilles Reuter, MD, PhD, and Britta wandschneider,...
Okay, here’s a draft article based on the provided text, aiming to meet all the specified requirements. It’s significantly expanded with SEO considerations, semantic branching, and the required components. I’ve included placeholders for data tables and further expert analysis where appropriate. Please read the “Important Notes” section at the end before publishing.
“`html
Depo-Provera (DMPA) Linked to Increased Meningioma Risk in Women: A Comprehensive Guide
A population-based study published in JAMA Neurology reveals that women using depot medroxyprogesterone acetate (DMPA, depo-Provera; Pfizer)-a long-acting injectable contraceptive-face a notably higher risk of being diagnosed with meningioma compared with women who use other contraceptives or none at all.1 This finding raises important questions about the safety profile of DMPA and warrants careful consideration by both patients and healthcare providers.
meningiomas represent the most common form of primary brain tumor, and although most are noncancerous, they remain clinically significant. The tumors occur relatively infrequently, with an annual incidence of about 6 to 8 cases per 100,000 people, and are most frequently enough diagnosed in middle age. Meningiomas are far more common in women than in men, with incidence increasing after puberty and a female-to-male ratio ranging from 2 to 3.5 to 1. Research suggests that female sex hormones play a role in both the advancement and growth of these tumors.2
“Meningioma is the only intracranial tumor with a clear predominance in women,with increasing incidence after puberty (from 2 to 3.5:1),” wrote Gilles Reuter, MD, PhD, and Britta wandschneider, MD, PhD, in an accompanying statement. ”Over 60% of meningiomas express progesterone receptors.”2
The Study: Methodology and Findings
A research team, led by investigators from the Cleveland Clinic and Case Western Reserve University, analyzed data from the TriNetX database, which includes records from 68 health care organizations